RheoCare SIGNED
Rheological Monitoring of Chronic Respiratory Diseases
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0RheoCare project word cloud
Explore the words cloud of the RheoCare project. It provides you a very rough idea of what is the project "RheoCare" about.
Project "RheoCare" data sheet
The following table provides information about the project.
| Coordinator |
RHEONOVA SAS
Organization address contact info |
| Coordinator Country | France [FR] |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-1 |
| Funding Scheme | SME-1 |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-12-01 to 2020-05-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | RHEONOVA SAS | FR (GRENOBLE) | coordinator | 50˙000.00 |
Map
Project objective
Chronic respiratory diseases are expected to become the third cause of mortality worldwide by 2020. Patients experience periodic acute exacerbation phases favouring infections of the lower airways and causing irreversible loss of pulmonary capacity. These crises cannot be forecast with current techniques and require emergency hospitalisations, leading to healthcare costs (€24k per crisis) and antibioresistances due to wide-spectrum treatments. Among respiratory diseases, we choose to target cystic fibrosis (CF) in Europe as organised care structures pre-exist. CF also represents a very attractive market segment of $4.5B across the Group of Eight (G8). Rheonova develops a unique monitoring test based on the rheology of lung secretions (mucus). The RheoCare project will provide a dedicated plug-and-play rheometer, with a quantitative biomarker and a specificity above 80%, allowing a point-of-care CF monitoring test within 10 minutes as a first step towards personalised healthcare. Our four-patent-protected technique already assesses treatments efficiency and is commercialised to researchers. Phase 1 clinical trials have demonstrated the reproducibility and the robustness of our biomarkers. Two new clinical protocols (Phase 2) proceed in order to demonstrate the medical benefit for the patient, i.e. the reduction of hospitalisations by predicting the exacerbation phases and assessing treatment performance quantitatively. Within three years, Phase 3 clinical trials will support the commercialisation of the device in EU and China. We will address the medical market with an attractively-priced machine accompanied with specific consumables needed to test mucus samples. To support our ambition, we need to implement an automated sample manipulation device. Three priority tasks remain to complete the feasibility study: (i) remoulding the software, (ii) supporting our commercialisation plan, and (iii) defining the IP strategy regarding this new building block.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RHEOCARE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "RHEOCARE" are provided by the European Opendata Portal: CORDIS opendata.